6SAUNDERS N J.Why monitor peak vancomycin concentration?[J].Lancet,1994,344(8939-8940):1748-1750.
7ZIMMERMANN A E,KATONA B G,PLAISANCE K I.Association of vancomycin serum concentration with outcomes in patients with gram-positive bacteremia[J].Pharmacotherapy,1995,15(1):85-91.
5Foote EF, Dreitlein WB,Steward CA.Pharmacokinetics of vancomycin when administered during high flux hemodialysis.Clin Nephrol,1998,50(1): 51-55.
6Barth RH,DeVincenzo N.Use of vancomycin in high- flux hemodialysis: experience with 130 courses of therapy.Kidney Int,1996,50(3): 929-936.
7Cohen E, Dadashev A, Drucker M,et al.Once- daily versus twice- daily intravenous administration of vancomycin for infections in hospitalized patients.J Antimicrob Chemother,2002,49(1): 155-160.
8Tanaka M,Orii T.Kobayashi H,et al.Examination of factors affecting efficacy and adverse effect, for the retrospective study of vancomycin hydrochloride(VCM).药学杂?,2001.121(8): 621-629.
9I,eader WG,Chandler M,Castiglia M.Pharmacikinetics optimization of vaneomycin therapy[J].Clin Pharmacokinet,1995,28:327-342.
10Rybak MJ,Albrecht LM,Boike SC,et al.Nephrotoxicity of vancomycin,alone and with an aminoglucoside.[J].Antimicrob chemother,1990,25(4):679.
